{
    "clinical_study": {
        "@rank": "83825", 
        "arm_group": {
            "arm_group_label": "18F-FLT", 
            "arm_group_type": "Other", 
            "description": "18F-FLT PET for Suspicious Findings on Mammography and Breast Ultrasound."
        }, 
        "brief_summary": {
            "textblock": "The purpose: To investigate the diagnostic accuracy of 18F-FLT PET for the suspicious\n      lesions on mammograms and ultrasound."
        }, 
        "brief_title": "18F-FLT PET for Suspicious Findings on Mammography and Breast Ultrasound", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "1. To investigate the diagnostic accuracy of 18F-FLT PET for the suspicious lesions on\n           mammograms and ultrasound, using the pathologic result of biopsy as gold standard, and\n           to determine whether 18F-FLT PET can increase the specificity in breast lesion\n           diagnosis and thus reduce the unnecessary biopsy.\n\n        2. To evaluate whether 18F-FLT PET is a cost-effective imaging modality for breast cancer\n           diagnosis."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Women aged between 20 to 80 years\n\n          2. women who have localized findings on mammography and / or ultrasound and will receive\n             biopsy.\n\n          3. The lesions on the conventional imaging measure >=1cm\n\n          4. WBC count >=3000/L, or platelet>=75,000/L\n\n          5. Liver function, AST or ALT < 78 U/L\n\n          6. Renal function, Creatinine < 2.0 mg/dl.The laboratory examinations should be\n             performed within 4months before our study.\n\n        Exclusion Criteria:\n\n          1. Pregnant women or who are planning to be pregnant.\n\n          2. Known cancers in other organs.\n\n          3. Women who are not able to cooperate with the PET/CT examination."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01713049", 
            "org_study_id": "201001043M"
        }, 
        "intervention": {
            "arm_group_label": "18F-FLT", 
            "description": "0.07 mCi/kg of 18F-FDG will be injected intravenously. The data acquisition will be started at 90 minutes after the injection using 2-D acquisition from a GE DISCOVERY ST PET/CT scanner (GE Medical Systems, Milwaukee, WI).", 
            "intervention_name": "18F-FLT", 
            "intervention_type": "Drug", 
            "other_name": "FLT"
        }, 
        "intervention_browse": {
            "mesh_term": "Alovudine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "FLT PET", 
            "breast neoplasms", 
            "mammography", 
            "breast ultrasound"
        ], 
        "lastchanged_date": "October 23, 2012", 
        "location": {
            "contact": {
                "email": "hstjen@yahoo.com.tw", 
                "last_name": "Jane Wang, MD, PhD", 
                "phone": "+886-2-23123456", 
                "phone_ext": "65565"
            }, 
            "facility": {
                "address": {
                    "city": "Taipei", 
                    "country": "Taiwan", 
                    "zip": "100"
                }, 
                "name": "Department of Medical Imaging NTUH"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_arms": "1", 
        "official_title": "Use of 18F-FLT Positron Emission Tomography to Evaluate the Suspicious Findings on Mammography and Breast Ultrasound: A Pilot Study", 
        "overall_official": {
            "affiliation": "National Taiwan University Hospital", 
            "last_name": "Jane Wang, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "To investigate the diagnostic accuracy of 18F-FLT PET for the suspicious lesions on mammograms and ultrasound, using the pathologic result of biopsy as gold standard.", 
            "safety_issue": "Yes", 
            "time_frame": "The biopsy procedures will be scheduled as soon as possible and should be finished within 2 months after 18F-FLT PET."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01713049"
        }, 
        "responsible_party": {
            "investigator_affiliation": "National Taiwan University Hospital", 
            "investigator_full_name": "National Taiwan University Hospital", 
            "investigator_title": "National Taiwan University Hospital", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "National Taiwan University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Taiwan University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2010", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "August 2010"
    }
}